Stay updated on FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial
Sign up to get notified when there's something new on the FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial page.

Latest updates to the FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial page
- CheckyesterdayChange DetectedDifference0.4%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.6%
- Check15 days agoChange DetectedDifference0.7%
- Check22 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a Phase I study involving FT596, Rituximab, and Obinutuzumab for B-cell lymphoma and chronic lymphocytic leukemia. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference17%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.7%
- Check37 days agoChange DetectedThe page has been updated to reflect a change in terminology from 'Lymphosarcoma' to 'B-cell Lymphoma' and has been revised from version 2.14.2 to 2.14.3.SummaryDifference0.7%
Stay in the know with updates to FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial page.